Theranostics in nuclear medicine gathers researchers’ interest through molecular imaging and personalized medicine. This is achieved through assistance in the management of various diseases, improves patient selection process, predicts drug response and toxicity, determines prognosis, and helps avoid futile and costly/expensive examinations and treatments. The theranostic approach to nuclear medicine involves a combination of diagnostic imaging and therapy based on a radioactive drug; its primary focus is the diagnosis, while the secondary focus is the treatment of a tumor site. Radioiodine was the first theranostic radiopharmaceutical used in treating and imaging thyroid diseases. In radioiodine therapy, the radioisotope iodine-131 is a gamma and beta emitter, and the sodium-iodide symporter can directly mediate the gamma emitter to thyroid cells. Further, gamma and positron emitters (β+) are used in nuclear imaging. Gamma emitters such as technetium-99m or iodine-123 are used in SPECT imaging, whereas the use of gallium-68 and fluorine-18 in PET imaging can provide better resolution. Therefore, theranostics-based nuclear-targeted therapies are emerging as a useful tool for treating patients suffering from advanced neuroendocrine and gastroenteropancreatic tumors such as neuroblastomas.
The Asia Pacific radiopharmaceutical theranostics market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. China held the largest share of the market in 2021, and India is expected to exhibit a significant growth pace in the market during the forecast period. The market growth in these countries is attributed to the rising chronic disease prevalence and favorable reimbursement policies. Moreover, expansion and product launch strategies implemented by market players are expected to contribute to the growth of the radiopharmaceutical theranostics market in the region.
Asia Pacific Radiopharmaceutical Theranostics Market Segmentation
The Asia Pacific radiopharmaceutical theranostics market is segmented into product type, Radioisotope, source, application, indication, end user, and country. Based on product type, the Asia Pacific radiopharmaceutical theranostics market is segmented into alpha emitters, beta emitters, and positron emission tomography (PET) tracers. The PET tracers segment held the largest market share in 2022.
Based on Radioisotope, the Asia Pacific radiopharmaceutical theranostics market is segmented into technetium-99, gallium-68, iodine-131, iodine-123, Fluorine-18 (18F), Yttrium 90 (Y-90), Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, and others. The Lutetium (Lu) 177 segment held the largest market share in 2022.
Based on source, the Asia Pacific radiopharmaceutical theranostics market is bifurcated into nuclear reactors and cyclotrons. The cyclotrons segment held a larger market share in 2022.
Based on application, the Asia Pacific radiopharmaceutical theranostics market is bifurcated into targeted therapeutic (Rx) and Companion Diagnostic (CDx). The targeted therapeutic (Rx) segment held a larger market share in 2022.
Based on indication, the Asia Pacific radiopharmaceutical theranostics market is segmented into oncology, cardiology, neurology, and others. The oncology segment held the largest market share in 2022.
Based on end user, the Asia Pacific radiopharmaceutical theranostics market is segmented into hospitals, diagnostic imaging centers, academic and research institutes, and others. The oncology segment held the largest market share in 2022.
Based on country, the Asia Pacific radiopharmaceutical theranostics market is segmented into China, India, Japan, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific radiopharmaceutical theranostics market share in 2022.
Bayer AG, GE Healthcare Technologies Inc., Curium, Telix Pharmaceuticals Ltd., and Cardinal Health Inc. are among the leading companies operating in the Asia Pacific radiopharmaceutical theranostics market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 337.53 Million |
| Market Size by 2028 | US$ 667.40 Million |
| CAGR (2022 - 2028) | 12.0% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2028 |
| Segments Covered |
By Product Type
|
| Regions and Countries Covered |
Asia-Pacific
|
| Market leaders and key company profiles |
|
The Asia Pacific Radiopharmaceutical Theranostics Market is valued at US$ 337.53 Million in 2022, it is projected to reach US$ 667.40 Million by 2028.
As per our report Asia Pacific Radiopharmaceutical Theranostics Market, the market size is valued at US$ 337.53 Million in 2022, projecting it to reach US$ 667.40 Million by 2028. This translates to a CAGR of approximately 12.0% during the forecast period.
The Asia Pacific Radiopharmaceutical Theranostics Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Radiopharmaceutical Theranostics Market report:
The Asia Pacific Radiopharmaceutical Theranostics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Radiopharmaceutical Theranostics Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Radiopharmaceutical Theranostics Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Asia Pacific Radiopharmaceutical Theranostics Market
